Business Description
Blueprint Medicines Corp
NAICS : 325412
SIC : 2834
ISIN : US09627Y1091
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.96 | |||||
Equity-to-Asset | 0.3 | |||||
Debt-to-Equity | 1.06 | |||||
Debt-to-EBITDA | -1.33 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.63 | |||||
Beneish M-Score | -2.2 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -33.7 | |||||
3-Year Book Growth Rate | -56.2 | |||||
Future 3-5Y Total Revenue Growth Rate | 49.73 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 76.54 | |||||
9-Day RSI | 72.91 | |||||
14-Day RSI | 68.41 | |||||
6-1 Month Momentum % | 51.74 | |||||
12-1 Month Momentum % | 65.87 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.76 | |||||
Quick Ratio | 3.61 | |||||
Cash Ratio | 3.14 | |||||
Days Inventory | 880.14 | |||||
Days Sales Outstanding | 54.03 | |||||
Days Payable | 291.29 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.9 | |||||
Shareholder Yield % | -2.23 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 96.97 | |||||
Operating Margin % | -155.18 | |||||
Net Margin % | -102.15 | |||||
FCF Margin % | -152.6 | |||||
ROE % | -105.26 | |||||
ROA % | -26.11 | |||||
ROIC % | -109.34 | |||||
ROC (Joel Greenblatt) % | -227.32 | |||||
ROCE % | -28.55 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 23.34 | |||||
PB Ratio | 21.49 | |||||
Price-to-Tangible-Book | 21.49 | |||||
EV-to-EBIT | -24.45 | |||||
EV-to-EBITDA | -25.71 | |||||
EV-to-Revenue | 22.55 | |||||
EV-to-Forward-Revenue | 14.46 | |||||
EV-to-FCF | -14.8 | |||||
Price-to-Net-Current-Asset-Value | 136.9 | |||||
Earnings Yield (Greenblatt) % | -4.09 | |||||
FCF Yield % | -6.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Blueprint Medicines Corp Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 260.551 | ||
EPS (TTM) (€) | -4.463 | ||
Beta | 0.3 | ||
Volatility % | 53.94 | ||
14-Day RSI | 68.41 | ||
14-Day ATR (€) | 2.944615 | ||
20-Day SMA (€) | 89.306 | ||
12-1 Month Momentum % | 65.87 | ||
52-Week Range (€) | 41.2 - 102 | ||
Shares Outstanding (Mil) | 62.62 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Blueprint Medicines Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Blueprint Medicines Corp Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Blueprint Medicines Corp Frequently Asked Questions
What is Blueprint Medicines Corp(FRA:2L9)'s stock price today?
When is next earnings date of Blueprint Medicines Corp(FRA:2L9)?
Does Blueprint Medicines Corp(FRA:2L9) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |